AbbVie Inc (ABBV)vsConcentra Group Holdings Parent, Inc. (CON)
ABBV
AbbVie Inc
$211.32
+3.64%
HEALTHCARE · Cap: $360.63B
CON
Concentra Group Holdings Parent, Inc.
$22.47
+0.36%
HEALTHCARE · Cap: $2.90B
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 2727% more annual revenue ($61.16B vs $2.16B). CON leads profitability with a 7.7% profit margin vs 6.9%. CON trades at a lower P/E of 17.4x. ABBV earns a higher WallStSmart Score of 63/100 (C+).
ABBV
Buy63
out of 100
Grade: C+
CON
Buy59
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-29.3%
Fair Value
$163.42
Current Price
$211.32
$47.90 premium
Margin of Safety
+66.5%
Fair Value
$72.22
Current Price
$22.47
$49.75 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Growing faster than its price suggests
Every $100 of equity generates 62 in profit
Strong operational efficiency at 34.1%
Conservative balance sheet, low leverage
Generating 4.9B in free cash flow
Every $100 of equity generates 48 in profit
Earnings expanding 60.1% YoY
Attractively priced relative to earnings
15.9% revenue growth
Areas to Watch
6.9% margin — thin
Premium valuation, high expectations priced in
Earnings declined 88.7%
Distress zone — elevated risk
7.7% margin — thin
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, PEG Ratio, Return on Equity. PEG of 0.48 suggests the stock is reasonably priced for its growth.
Bull Case : CON
The strongest argument for CON centers on Return on Equity, EPS Growth, P/E Ratio. Revenue growth of 15.9% demonstrates continued momentum.
Bear Case : ABBV
The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 100.0x leaves little room for execution misses.
Bear Case : CON
The primary concerns for CON are Profit Margin, Piotroski F-Score.
Key Dynamics to Monitor
ABBV profiles as a value stock while CON is a growth play — different risk/reward profiles.
CON is growing revenue faster at 15.9% — sustainability is the question.
ABBV generates stronger free cash flow (4.9B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
ABBV scores higher overall (63/100 vs 59/100). CON offers better value entry with a 66.5% margin of safety. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Concentra Group Holdings Parent, Inc.
HEALTHCARE · MEDICAL CARE FACILITIES · USA
Concentra Group Holdings Parent, Inc. (Ticker: CON) is a diversified holding company that specializes in acquiring and managing businesses in high-growth sectors such as healthcare, technology, and infrastructure. With a commitment to operational excellence and innovation, Concentra leverages its seasoned leadership team to enhance portfolio performance through strategic investments and proactive management. This forward-looking approach positions the company to effectively capitalize on emerging trends and opportunities, making it an attractive investment for institutional investors aiming to diversify into high-potential industries.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?